Tech Center 1600 • Art Units: 1621 1624
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17497633 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | Final Rejection | Hoffmann-La Roche Inc. |
| 18262429 | METHOD FOR THE CONTROL OR SUPPRESSION OF PHYTOPATHOGENIC BACTERIA | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18022962 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18559017 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | Non-Final OA | THE GEORGE WASHINGTON UNIVERSITY |
| 18283264 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17906580 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | Final Rejection | ELI LILLY AND COMPANY |
| 18176877 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 18546322 | RADIOLABELED COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Research Foundation for the State University of New York |
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | Final Rejection | TONGJI UNIVERSITY |
| 17597166 | IRAK DEGRADERS AND USES THEREOF | Final Rejection | Kymera Therapeutics, Inc. |
| 17768003 | ANTIVIRAL COMPOUNDS AND METHODS | Final Rejection | THE UNIVERSITY OF NOTTINGHAM |
| 18010735 | ORAL FORMULATIONS AND USES THEREOF | Final Rejection | INVENTISBIO CO., LTD. |
| 18577261 | COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF | Non-Final OA | TYK MEDICINES (ZHENGZHOU), INC. |
| 18256091 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Erasca, Inc. |
| 18027313 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Erasca, Inc. |
| 18568448 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | Non-Final OA | ONQUALITY PHARMACEUTICALS CHINA LTD. |
| 18568498 | INTERMEDIATE FOR PREPARING FULVESTRANT AND PREPARATION METHOD THEREFOR | Non-Final OA | SHANGHAI BEST-LINK BIOSCIENCE, LLC |
| 18568686 | METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE | Non-Final OA | Neuronascent, Inc. |
| 18568761 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | Non-Final OA | TYK MEDICINES, INC. |
| 18563275 | INSECT REPELLANT FORMULATION AND METHOD OF USING SAME | Non-Final OA | ROSS LIFESCIENCE PRIVATE LIMITED |
| 18559020 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | Non-Final OA | Institut National de la Santé et de la Recherche Médicale - INSERM |
| 18251501 | Compounds | Final Rejection | University Court of the University of St Andrews |
| 18041617 | OSIMERTINIB AND SELPERCATINIB COMBINATIONS FOR THE TREATMENT OF EGFR- AND RET-ASSOCIATED CANCERS | Non-Final OA | Loxo Oncology, Inc. |
| 18373906 | TREATMENT OF MENTAL DISORDERS | Non-Final OA | GH Research Ireland Limited |
| 18039644 | CARBONIC ANHYDRASE INHIBITORS SYNTHESIZED ON INTERCONNECTING LINKER CHAINS | Non-Final OA | VILNIUS UNIVERSITY |
| 18453324 | Cosmetic Skin and Medical Cream | Non-Final OA | Protecta-Skincare, Inc. |
| 18452606 | AGAROFURAN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | BEIJING CHY PHARMACEUTICAL TECHNOLOGY CO, LTD. |
| 18015445 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Non-Final OA | AGENEBIO, INC. |
| 18042485 | COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL | Non-Final OA | ViiV Healthcare Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy